157 related articles for article (PubMed ID: 35709412)
1. Metastatic Rhabdomyosarcoma: Results of the European
Schoot RA; Chisholm JC; Casanova M; Minard-Colin V; Geoerger B; Cameron AL; Coppadoro B; Zanetti I; Orbach D; Kelsey A; Rogers T; Guizani C; Elze M; Ben-Arush M; McHugh K; van Rijn RR; Ferman S; Gallego S; Ferrari A; Jenney M; Bisogno G; Merks JHM
J Clin Oncol; 2022 Nov; 40(32):3730-3740. PubMed ID: 35709412
[TBL] [Abstract][Full Text] [Related]
2. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G; De Salvo GL; Bergeron C; Gallego Melcón S; Merks JH; Kelsey A; Martelli H; Minard-Colin V; Orbach D; Glosli H; Chisholm J; Casanova M; Zanetti I; Devalck C; Ben-Arush M; Mudry P; Ferman S; Jenney M; Ferrari A;
Lancet Oncol; 2019 Nov; 20(11):1566-1575. PubMed ID: 31562043
[TBL] [Abstract][Full Text] [Related]
4. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Bisogno G; Jenney M; Bergeron C; Gallego Melcón S; Ferrari A; Oberlin O; Carli M; Stevens M; Kelsey A; De Paoli A; Gaze MN; Martelli H; Devalck C; Merks JH; Ben-Arush M; Glosli H; Chisholm J; Orbach D; Minard-Colin V; De Salvo GL;
Lancet Oncol; 2018 Aug; 19(8):1061-1071. PubMed ID: 29941280
[TBL] [Abstract][Full Text] [Related]
5. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).
Chisholm JC; Merks JHM; Casanova M; Bisogno G; Orbach D; Gentet JC; Thomassin-Defachelles AS; Chastagner P; Lowis S; Ronghe M; McHugh K; van Rijn RR; Hilton M; Bachir J; Fürst-Recktenwald S; Geoerger B; Oberlin O;
Eur J Cancer; 2017 Sep; 83():177-184. PubMed ID: 28738258
[TBL] [Abstract][Full Text] [Related]
6. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
7. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
9. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
Sparber-Sauer M; Ferrari A; Kosztyla D; Ladenstein R; Cecchetto G; Kazanowska B; Scarzello G; Ljungman G; Milano GM; Niggli F; Alaggio R; Vokuhl C; Casanova M; Klingebiel T; Zin A; Koscielniak E; Bisogno G
Pediatr Blood Cancer; 2022 Sep; 69(9):e29691. PubMed ID: 35441463
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
[TBL] [Abstract][Full Text] [Related]
11. Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group.
Ferrari A; Orbach D; Casanova M; van Noesel MM; Berlanga P; Brennan B; Corradini N; Schoot RA; Ramirez-Villar GL; Hjalgrim LL; Alaggio R; Guillen Burrieza G; Safwat A; Cameron AL; van Rijn RR; Minard-Colin V; Zanetti I; Bisogno G; Chisholm JC; Merks JHM
Cancer; 2023 Aug; 129(16):2542-2552. PubMed ID: 37084075
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C
Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
[TBL] [Abstract][Full Text] [Related]
14. Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005.
Brennan B; De Salvo GL; Orbach D; De Paoli A; Kelsey A; Mudry P; Francotte N; Van Noesel M; Bisogno G; Casanova M; Ferrari A
Eur J Cancer; 2016 Jun; 60():69-82. PubMed ID: 27082136
[TBL] [Abstract][Full Text] [Related]
15. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
[TBL] [Abstract][Full Text] [Related]
16. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
Orbach D; Rey A; Oberlin O; Sanchez de Toledo J; Terrier-Lacombe MJ; van Unnik A; Quintana E; Stevens MC
J Clin Oncol; 2005 Jul; 23(19):4363-71. PubMed ID: 15994146
[TBL] [Abstract][Full Text] [Related]
17. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
18. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
20. The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
Bisogno G; Ferrari A; Bergeron C; Scagnellato A; Prete A; Alaggio R; Casanova M; D'Angelo P; Di Cataldo A; Carli M
Cancer; 2005 Apr; 103(8):1719-24. PubMed ID: 15754335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
